MedTrace Logo

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

NCT07308639 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50000

Last updated 2026-04-13

No results posted yet for this study

Summary

The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are:

nAMD (neovascular age-related macular degeneration): a condition that affects the central part of the retina and can cause vision loss in older adults.

DME (diabetic macular edema): a swelling in the central part of the retina caused by diabetes, which can also lead to vision problems.

RVO (retinal vein occlusion): a blockage of the veins in the retina, which can cause sudden vision loss.

Researchers will look at data collected from 2009 to 2024 to see how often these diseases occur (incidence) and how many people have them at a given time (prevalence). They will use two large sets of health data from Germany, called FDZ and FDGP.

The main question is: How do the numbers of new and existing cases of nAMD, DME, and RVO compare between the two data sources (FDZ and FDGP) in Germany from 2009 to 2024? The study also wants to find out if factors like age, other health problems, and medications affect how common these eye diseases are.

Another goal is to see how many people with these eye diseases are treated with a type of medicine called anti-VEGF, which is used to slow down or stop vision loss.

In summary, this study will help us understand how these eye diseases affect people in Germany, how they are treated, and whether different groups of people are more likely to get them.

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

Interventions

DRUG

anti-VEGF medication

according to local label and treating physician

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-03
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07308639 on ClinicalTrials.gov